Glutamine

Presentation Slides

Chinese Medicine Research Hub

Systematic Review

Parenteral glutamine supplementation given in conjunction with nutrition support continues to be associated with a significant reduction in hospital mortality and hospital length of stay.

2014 Critical Care Parenteral glutamine supplementation in critical illness: a systematic review
Paul E Wischmeyer, Rupinder Dhaliwal, Michele McCall, Thomas R Ziegler & Daren K Heyland

Executive Summary

Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Glutamine" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.

Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Glutamine" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.

Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Glutamine" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.

A Systematic Review published in 2014 in the journal Critical Care found that Parenteral glutamine supplementation given in conjunction with nutrition support continues to be associated with a significant reduction in hospital mortality and hospital length of stay. In this comprehensive systematic review, we demonstrate that traditional parenteral glutamine (GLN) supplementation as a component of nutrition support (primarily added to PN) is associated with a significant decrease in hospital mortality and length of hospital stay. GLN supplementation is also associated with trends towards reduced overall mortality, infectious complications and ICU LOS in critically ill patients. The therapeutic effect may be dependent on GLN dose given, with optimal benefit traditionally observed between 0.3 and 0.5 g/kg/d. Thus, we recommend that parenteral GLN supplementation as a component of nutrition support be considered as an approach to improve outcomes of critical illness in selected patients. Our data here suggest that parenteral GLN supplementation, as a component of complete PN and/or EN support, is safe when administered following resolution of shock and multi-organ failure, and with daily doses less the 0.5 g/kg/d.

Moderation Tools

Topic